NCT01043952

Brief Summary

The objective of the study is to determine wether the use of the Bispectral Index Monitor (BIS) as a method to guide anaesthesia for children in different groups of age, undergoing ear nose and throat surgery anaesthetized with an infusion of Propofol and Remifentanil with an high dose of Remifentanil (0,5-2 mcg/kg/min), can lead to a reduction in the time needed for extubation and in the amount of anesthetics used.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
157

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2010

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2010

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

January 4, 2010

Completed
3 days until next milestone

First Posted

Study publicly available on registry

January 7, 2010

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2012

Completed
Last Updated

June 25, 2015

Status Verified

June 1, 2015

Enrollment Period

2.2 years

First QC Date

January 4, 2010

Last Update Submit

June 23, 2015

Conditions

Keywords

PropofolRemifentanilBispectral Index Monitor

Outcome Measures

Primary Outcomes (1)

  • Time to extubation since the interruption in the administration of anaesthetics.

    30 minutes-3 hours

Secondary Outcomes (3)

  • Consumption of Remifentanil at induction and during maintenance of general anesthesia.

    30 minutes-3 hours

  • Average BIS during the surgical procedure

    30min-3hours

  • Consumption of Propofol during the induction and maintenance of anesthesia.

    30 minutes-3 hours

Study Arms (2)

Control

ACTIVE COMPARATOR

Patients receive general anesthesia with Propofol and Remifentanil following clinical practice. Stratification by age (1-3 y, 4-11y, 12-17y, 18-65y) will be performed to ensure balanced allocation of age groups and allow for identification of age and weight specific effects. Stratification by operation type will be performed to ensure the identification of the effects of the duration of anaesthesia and of the use of longer acting opioids (Fentanyl) on outcome parameters.

Drug: PropofolDrug: Remifentanil

Bispectral Index Monitor

EXPERIMENTAL

Patients receive a general anesthesia with Propofol and Remifentanil where the amount of anesthetics administered is decided taking into consideration the Bispectral Index Monitor. Stratification by age (1-3 y, 4-11y, 12-17y, 18-65y) will be performed to ensure balanced allocation of age groups and allow for identification of age and weight specific effects. Stratification by operation type will be performed to ensure the identification of the effects of the duration of anaesthesia and of the use of longer acting opioids (Fentanyl) on outcome parameters.

Drug: PropofolDrug: RemifentanilDevice: Bispectral Index Monitor

Interventions

Propofol is used as an anesthetic drug on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.

Bispectral Index MonitorControl

Remifentanil is used as analgesic drug, as a part of the total intravenous anaesthesia, on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.

Also known as: Ultiva
Bispectral Index MonitorControl

Bispectral Index Monitor (BIS monitor integrated in the IntelliVue Patient monitor MP70, Philips) is used to monitor the depth of anesthesia. The values this monitor reports are used as an aid in evaluating the response of the single patient to the administered anesthetics, and as a guide in adjusting the dosing of anesthetics. We follow the algorithm from: http://www.biseducation.com/assets.aspx?ac=1 (ASA Practice Advisory White Paper)

Bispectral Index Monitor

Eligibility Criteria

Age1 Year - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • American Society of Anesthesiologists (ASA) physical status 1 or 2
  • General anesthesia for the following operations: Tonsillectomy, Adenoidectomy, Myringoplasty, Myringotomy with tube placement, microlaryngoscopy, bronchoscopy and esophagoscopy.

You may not qualify if:

  • Psychiatric disorder
  • Use of psychotherapeutic, antiepileptic, antiarrhythmic drugs
  • Chronic use of opioids
  • Intake of more than 21 alcoholic drinks/week
  • Missing informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Aalborg Hospital, 4th. dept of Anaesthesiology, Division for Ear Nose and Troath anaesthesia

Aalborg, Nord Jylland, 9800, Denmark

Location

Related Publications (1)

  • Bresil P, Nielsson MS, Malver LP, Kraemer K, Schjorring O, Dethlefsen C, Lambert PH. Impact of bispectral index for monitoring propofol remifentanil anaesthesia. A randomised clinical trial. Acta Anaesthesiol Scand. 2013 Sep;57(8):978-87. doi: 10.1111/aas.12158. Epub 2013 Jul 15.

MeSH Terms

Interventions

PropofolRemifentanilConsciousness Monitors

Intervention Hierarchy (Ancestors)

PhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPropionatesAcids, AcyclicCarboxylic AcidsPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsSurgical EquipmentEquipment and Supplies

Study Officials

  • Piergiorgio Bresil, MD

    Aalborg Hospital, 4th dept. of Anaesthesiology Region Nordjylland

    PRINCIPAL INVESTIGATOR
  • Per H Lambert, MD

    Aalborg Hospital, 4th. dept. of Anaesthesiology Region Nordjylland

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

January 4, 2010

First Posted

January 7, 2010

Study Start

January 1, 2010

Primary Completion

March 1, 2012

Study Completion

March 1, 2012

Last Updated

June 25, 2015

Record last verified: 2015-06

Locations